Tarsus Pharmaceuticals 

Yahoo Finance • 11 months ago

11 Stocks That Will Make You Rich in 5-10 Years

In this article, we will take a detailed look at the11 Stocks That Will Make You Rich in 5-10 Years. For a quick overview of such stocks, read our article 5Stocks That Will Make You Rich in 5-10 Years. Can investing in stocks make you ric... Full story

Yahoo Finance • last year

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

Launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis Achieved $1.7 million in net product sales with more than 1,700 dispensed bottles Strengthened balance sheet with an approximately $100 mill... Full story

Yahoo Finance • last year

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with ey... Full story

Yahoo Finance • last year

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with e... Full story

Yahoo Finance • last year

Tarsus to Present at Upcoming Investor Conferences

IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with ey... Full story

Yahoo Finance • last year

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available via prescription from an eye care provi... Full story

Yahoo Finance • 2 years ago

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

IRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with ey... Full story

Yahoo Finance • 2 years ago

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye... Full story

Yahoo Finance • 2 years ago

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with e... Full story

Yahoo Finance • 2 years ago

Shareholders in Tarsus Pharmaceuticals (NASDAQ:TARS) are in the red if they invested a year ago

The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. For example, the Tarsus Pharmaceuticals, Inc. (NASDAQ:T... Full story

Yahoo Finance • 2 years ago

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA Completed enrollment of Ersa, a Phase 2a trial evaluating TP-03 for MGD w... Full story

Yahoo Finance • 2 years ago

Tarsus Added to NASDAQ Biotechnology Index

IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with ey... Full story

Yahoo Finance • 2 years ago

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a Phase 2a Carpo trial to evaluate the safety, tolerability, and proof-of-activity of TP-05 in healthy subjects TP-05 desig... Full story

Yahoo Finance • 2 years ago

Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements

New Drug Application for TP-03 accepted; PDUFA target action date August 25, 2023 Launched disease education, field medical team and payor engagement in anticipation of TP-03 launch Cash runway anticipated into at least 2026 for the plan... Full story

Yahoo Finance • 2 years ago

Tarsus Announces Transition Plans for Board of Directors

Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will become Lead Independent Director and CEO Bobak Azamian will become Chairman upon Dr. Ackermann’s expected transition IRVINE, Calif., Oc... Full story

Yahoo Finance • 2 years ago

Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis

IRVINE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with e... Full story

Yahoo Finance • 2 years ago

Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements

TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; NDA submission expected this year Initiated Ersa Phase 2a trial evaluating TP-03 for the treatment of Meibomian Gland Disease Cash runway ant... Full story

Yahoo Finance • 2 years ago

Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease

IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with ey... Full story

Yahoo Finance • 2 years ago

Certara Appoints Rosemary Crane as New Independent Board Member

PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022. Her appointment brin... Full story

Yahoo Finance • 3 years ago

Tarsus to Present at the Jefferies 2022 Healthcare Conference

IRVINE, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye... Full story